Proteins and nucleic acids encoding same

Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

1 - 49 . (canceled)  
     
     
         50 . An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: 
 (a) SEQ ID NO: 46;    (b) a mature form of the amino acid sequence of SEQ ID NO: 46;    (c) a variant of the amino acid sequence of SEQ ID NO: 46, wherein one or more amino acid residues in said variant differ from SEQ ID NO: 46, provided that said variant differs in no more than 15% of amino acid residues from SEQ ID NO: 46;    (d) a variant of the amino acid sequence of SEQ ID NO: 46, wherein the amino acid sequence of said variant comprises one or more conservative amino acid substitutions to SEQ ID NO: 46.    
     
     
         51 . The isolated polypeptide of  claim 50  comprising an amino acid sequence of SEQ ID NO: 46.  
     
     
         52 . The isolated polypeptide of  claim 50  comprising a mature form of the amino acid sequence of SEQ ID NO: 46.  
     
     
         53 . The isolated polypeptide of  claim 50  comprising a variant of the amino acid sequence of SEQ ID NO: 46, wherein the amino acid sequence of said variant comprises one or more conservative amino acid substitutions to SEQ ID NO: 46.  
     
     
         54 . a pharmaceutical composition comprising the polypeptide of claim  1  and a pharmaceutically acceptable carrier.  
     
     
         55 . An antibody that binds immunospecifically to the polypeptide of claim  1 .  
     
     
         56 . The antibody of  claim 55 , wherein said antibody is a monoclonal antibody.  
     
     
         57 . The antibody of  claim 55 , wherein said antibody is a humanized antibody.  
     
     
         58 . A pharmaceutical composition comprising the antibody of  claim 55  and a pharmaceutically acceptable carrier.  
     
     
         59 . An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide selected from the group consisting of: 
 (a) a polypeptide of SEQ ID NO: 2, 6, or 36;    (b) a mature form of a polypeptide of SEQ ID NO: 2, 6, or 36;    (b) a polypeptide consisting of an amino acid sequence having one or more conservative amino acid substitutions to SEQ ID NO: 2, 6, or 36.    or a complement of said nucleotide sequence.    
     
     
         60 . The isolated nucleic acid molecule of  claim 59  comprising nucleotides 1-1083 of SEQ ID NO: 1.  
     
     
         61 . The isolated nucleic acid molecule of  claim 59  comprising nucleotides 1-10794 of SEQ ID NO: 5.  
     
     
         62 . The isolated nucleic acid molecule of  claim 59  comprising nucleotides 141-4580 of SEQ ID NO: 35.  
     
     
         63 . A vector comprising the nucleic acid molecule of  claim 59 .  
     
     
         64 . The vector of  claim 63  further comprising a promoter operably-linked to said nucleic acid molecule.  
     
     
         65 . A cell comprising the vector of  claim 63 .  
     
     
         66 . A pharmaceutical composition comprising the nucleic acid molecule of  claim 59 , and a pharmaceutically acceptable carrier.